日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis

在甲氨蝶呤治疗失败后，对已确诊类风湿性关节炎患者早期使用原研生物制剂或其生物类似药进行治疗的成本效益分析

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-019-00986-7
Patel, Dipen; Shelbaya, Ahmed; Cheung, Raymond; Aggarwal, Jyoti; Park, Sang Hee; Coindreau, Javier
关节炎
发表日期：2019
文献求助 收藏

Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey

拉丁美洲一项关于风湿病生物类似药有效药物警戒系统障碍的调查

期刊:Pharmacoepidemiology and Drug Safety
影响因子:2.4
doi:10.1002/pds.4785
Castañeda-Hernández, Gilberto; Sandoval, Hugo; Coindreau, Javier; Rodriguez-Davison, Luis Felipe; Pineda, Carlos
发表日期：2019
文献求助 收藏

Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products

依那西普 (Enbrel®) 预期拷贝数的变化：七种产品的多批次数据

期刊:MAbs
影响因子:5.6
doi:10.1080/19420862.2017.1387346
Brian Hassett, Morton Scheinberg, Gilberto Castañeda-Hernández, Mengtao Li, Uppuluri R K Rao, Ena Singh, Ehab Mahgoub, Javier Coindreau, Julie O'Brien, Steven M Vicik, Brian Fitzpatrick
发表日期：2018
文献求助 收藏

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician

在风湿病、胃肠病和皮肤病炎症性疾病的治疗中，参考生物制剂与生物类似药之间的转换：临床医生的注意事项

期刊:Current Rheumatology Reports
影响因子:3.9
doi:10.1007/s11926-017-0658-4
Moots, Robert; Azevedo, Valderilio; Coindreau, Javier L; Dörner, Thomas; Mahgoub, Ehab; Mysler, Eduardo; Scheinberg, Morton; Marshall, Lisa
炎症/感染
炎症
发表日期：2017
文献求助 收藏

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology

风湿病学中生物类似药和生物制剂仿制药的临床和监管视角

期刊:Rheumatology International
影响因子:2.9
doi:10.1007/s00296-016-3444-0
Mysler, Eduardo; Pineda, Carlos; Horiuchi, Takahiko; Singh, Ena; Mahgoub, Ehab; Coindreau, Javier; Jacobs, Ira
发表日期：2016
文献求助 收藏

Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis

生物标志物在骨关节炎治疗药物研发中的应用

期刊:Osteoarthritis and Cartilage
影响因子:9
doi:10.1016/j.joca.2010.08.019
Kraus, V B; Burnett, B; Coindreau, J; Cottrell, S; Eyre, D; Gendreau, M; Gardiner, J; Garnero, P; Hardin, J; Henrotin, Y; Heinegård, D; Ko, A; Lohmander, L S; Matthews, G; Menetski, J; Moskowitz, R; Persiani, S; Poole, A R; Rousseau, J-C; Todman, M
关节炎
发表日期：2011
文献求助 收藏